{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-017922","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2023-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.705526+00:00","generated_at":"2026-06-13T19:53:18.993188+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"DiaMedica raises $37.5M in private placement; FDA lifts clinical hold on ReMEDy2 stroke trial","bullets":["Raised $37.5M gross via 11,011,406 common shares at $3.40 each; management paid $3.91/share.","FDA lifted clinical hold on Phase 2/3 ReMEDy2 trial for DM199 in acute ischemic stroke.","Net proceeds to fund DM199 development and ReMEDy2 trial through interim analysis.","Private placement expected to close June 23, 2023; resale registration to be filed.","Related parties (board/management) invested $751,900; Craig-Hallum acted as placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-017922","json":"https://secwatch.observer/filing/0001437749-23-017922.json","markdown":"https://secwatch.observer/filing/0001437749-23-017922.md","text":"https://secwatch.observer/filing/0001437749-23-017922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774923017922/0001437749-23-017922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774923017922/dmtp20230620d_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T19:53:18.993188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d43b104a895efadb0cc35ce888367aea3bd42113","claim":"DiaMedica Therapeutics Inc. entered into Securities Purchase Agreement with accredited investors, including certain existing stockholders and certain directors and officers valued at gross proceeds of $37.5 million (effective 2023-06-21).","evidence_excerpt":"entered into securities purchase agreements (the “Securities Purchase Agreement”) with accredited investors, including certain existing stockholders and certain directors and officers (collectively, the “Purchasers”), pursuant to which the Company agreed to issue 11,011,406 common shares, no par value, of the Company (collectively, the “Shares”), in a private placement (the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401040/000143774923017922/0001437749-23-017922-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"accredited investors, including certain existing stockholders and certain directors and officers"},{"label":"Value","value":"gross proceeds of $37.5 million"},{"label":"Effective","value":"2023-06-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}